Rejuveron Life Sciences

What they do

Founded in 2019 by scientist Matthias Steger and visionary investor Christian Angermayer, Centenara Labs (formerly Rejuveron) operates a unique "hub and spoke" model in the longevity biotech sector. The firm acts as both an incubator and an investor, co-founding subsidiaries with world-class scientific entrepreneurs and taking majority stakes in promising clinical-stage assets. In September 2024, the firm rebranded to Centenara Labs to better reflect its mission of helping people maintain functional independence and live like centenarians, while positioning the company for potential public market opportunities and pharma partnerships. They are highly regarded in the European ecosystem for providing not just capital, but deep drug discovery expertise and state-of-the-art laboratory facilities.

What they look for

Centenara Labs focuses on translating scientific discoveries in the biology of aging into transformative medicines. Their thesis is built around targeting the fundamental "hallmarks of aging" (such as cellular senescence, telomere attrition, and stem cell exhaustion) to prevent, repair, or reverse age-related diseases and reduce the growing strain on global healthcare systems.

Stage

Pre-seed, Seed, Series A, Series B+

Sectors

Healthcare, Deeptech

Based

Baar, CH